AUTHORS
Selene Rubino, MD, Xi Zhang, MD Phd2, Kenneth Warrington, MD3, Matthew J Koster, MD4, Jenna Fernandez, Ph.D.5, Christy Finke, BS6, Aref Al-Kali, M.D.7, Naseema Gangat, MBBS8, Antoine N. Saliba, M.D.9, Abhishek Avinash Mangaonkar, MBBS10, Hassan B Alkhateeb, M.D.11, Rong He, MD12, David Viswanatha, MD13, Terra Lasho, PhD14, Cornelia Weyand, MD, PhD15, Mrinal M. Patnaik, MD, MBBS16
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Mutations in isocitrate dehydrogenase (IDH1/2) occur in approximately 20% of acute myeloid leukemia (AML), 5–7% of myelodysplastic syndromes (MDS), and are less frequent in other myeloid neoplasms, including chronic myelomonocytic leukemia (CMML). Neomorphic IDH1/2 activity generates the oncometabolite 2-hydroxyglutarate, resulting in widespread epigenetic dysregulation. Resistance to selective IDH inhibition may occur through isoform switching, whereby acquisition of an alternate IDH mutation restores 2-hydroxyglutarate production. However, the clinical evolution of patients harboring concurrent IDH1 and IDH2 mutations remains poorly understood.
Methods: We retrospectively identified adult patients with concurrent IDH1 and IDH2 mutations from next-generation sequencing performed on bone marrow or peripheral blood specimens for myeloid neoplasms across all three Mayo Clinic sites (2016–2026). Clinical characteristics, clonal evolution, treatment history, inflammatory manifestations, and outcomes were obtained by retrospective chart review.
Results: Among 13,293 next-generation sequencing samples, 17 patients with concurrent IDH1 and IDH2 mutations were identified. Thirteen (76%) were male, with a median age of 76 years (range 29.8–95.9). All dual-mutant cases involved IDH1 R132 and IDH2 R140 variants. Primary diagnoses included AML (n=8), MDS (n=5), CMML (n=2), hairy cell leukemia (n=1), and primary myelofibrosis (n=1); by the time dual IDH mutations were detected, 13 patients had AML, 2 MDS, and 2 CMML.
Dual mutations developed simultaneously in 11 patients, whereas sequential acquisition occurred in six. IDH1 preceded IDH2 in four cases (all AML), while IDH2 preceded IDH1 in two cases (CMML and MDS). SRSF2 (n=9), ASXL1 (n=5), RUNX1 (n=5), and TET2 (n=4) were the most frequent cooperating mutations. Azacitidine represented the most common identifiable selective pressure preceding dual-mutant evolution (n=6), although no clear selection pressure was identified in five patients.
Among eight patients followed longitudinally during selective IDH inhibition, suppression of one mutant clone was consistently accompanied by expansion of the alternate IDH-mutant clone. In two patients, the second IDH mutation emerged only after initiation of selective IDH inhibition, with acquisition of mutant IDH2 following ivosidenib and mutant IDH1 following enasidenib, consistent with isoform switching as a mechanism of therapeutic resistance.
Inflammatory manifestations occurred in two patients, including inflammatory arthritis and polymyalgia rheumatica. Two additional patients had longstanding autoimmune disease preceding development of their myeloid neoplasm without disease flare at diagnosis.
One patient with IDH1/IDH2/SRSF2-mutant MDS and severe inflammatory arthritis was treated off-label with vorasidenib for inflammatory symptoms and cytopenias. Within three months, both inflammatory arthritis and cytopenias completely resolved despite minimal change in IDH1/2 clonal burden at both 3 and 6 months. Single-cell proteogenomic analysis demonstrated spatially distinct mutant clones, with IDH1 mutations detected in myeloid, T-, B-, and NK-cell compartments, whereas IDH2 mutations were restricted to myeloid cells, suggesting that mutant IDH may drive inflammatory phenotypes independent of measurable clonal response.
Conclusions: Dual IDH-mutant myeloid neoplasms demonstrate dynamic clonal competition and isoform switching under therapeutic pressure. The rapid clinical response to pan-IDH inhibition despite stable mutant clone size suggests that mutant IDH exerts non-cell-autonomous immunomodulatory effects, identifying inflammation as a potentially targetable consequence of mutant IDH biology.
DISCLOSURES
Selene Rubino, MD: No relevant conflicts of interest to declare.